Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2018 08:19 ET | Source: Biomerica, Inc.

Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea

IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent...
June 25, 2018 08:19 ET | Source: Biomerica, Inc.

Biomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy

Diagnostic Guided Therapy (DGT) is designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptomsApproximately 45 million Americans suffer from IBS1 Studies...
April 19, 2018 08:19 ET | Source: Biomerica, Inc.

Biomerica adds Harry Leider, MD, MBA to Strategic Advisory Board

IRVINE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today announced that it has added Harry L. Leider, MD, MBA to its Strategic Advisor Board, which is chaired by Edward...
April 17, 2018 09:00 ET | Source: Biomerica, Inc.

Biomerica Announces Third Quarter Financial Results

IRVINE, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $4,433,785 for the nine months ending February 28, 2018, compared to $4,342,247 for the...
March 08, 2018 08:19 ET | Source: Biomerica, Inc.

Mexico’s COFEPRIS (Mexico’s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer

IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced the Mexico’s COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios - Mexico’s equivalent...
January 16, 2018 09:18 ET | Source: Biomerica, Inc.

Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter

IRVINE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,613,636 for the three months ended November 30, 2017, compared to $1,432,206 for the...
January 10, 2018 08:19 ET | Source: Biomerica, Inc.

China Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer

IRVINE, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced the China Food and Drug Administration (CFDA) approval of the EZ Detect™ colorectal screening test designed...
January 08, 2018 08:19 ET | Source: Biomerica, Inc.

Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)

- DGT Designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptoms - DGT can be used alongside current IBS drug treatments to potentially improve...
November 07, 2017 08:19 ET | Source: Biomerica, Inc.

Biomerica Extends Exclusive License Agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019

IRVINE, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA) today announced that it has extended its exclusive license agreement with Celtis Pharm Co. Ltd of South Korea. Celtis...
October 17, 2017 08:19 ET | Source: Biomerica, Inc.

Biomerica Reports 1st Quarter Fiscal 2018 Financials

IRVINE, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,444,483 for the three months ending August 31, 2017, compared to $1,410,110 for the...